**Core Concept**
Acute bronchial asthma is a reversible airway obstruction caused by bronchospasm, inflammation, and mucous secretion. The management of acute asthma involves relieving bronchospasm, reducing inflammation, and managing symptoms.

**Why the Correct Answer is Right**
Montelukast is a leukotriene receptor antagonist (LTRA) that is primarily used in the long-term management of asthma as an add-on therapy to inhaled corticosteroids (ICS). It is not indicated for the acute treatment of bronchial asthma. In acute asthma, relief of bronchospasm is the primary goal, and LTRAs like montelukast do not provide rapid bronchodilation.

**Why Each Wrong Option is Incorrect**
**Option A:** Ipratropium is an anticholinergic agent that can be used in the treatment of acute asthma, particularly in patients with severe bronchospasm or those who are unresponsive to beta-agonists like salbutamol. It works by inhibiting the parasympathetic nervous system, which causes bronchoconstriction.

**Option B:** Salbutamol is a short-acting beta-2 agonist (SABA) that is the first-line treatment for acute bronchial asthma. It rapidly reverses bronchospasm and improves airflow by stimulating beta-2 receptors in the bronchial smooth muscle.

**Option D:** Hydrocortisone is a corticosteroid that is used in the treatment of acute asthma to reduce inflammation and prevent exacerbations. Corticosteroids are essential in the management of acute asthma, particularly in patients with severe disease or those who require hospitalization.

**Clinical Pearl / High-Yield Fact**
In acute asthma, the "5-2-1" rule is a useful clinical guideline: a patient with acute asthma should have a peak expiratory flow (PEF) of at least 50% of their predicted value, be able to speak in complete sentences, be able to walk 20 feet without dyspnea, and have a respiratory rate of 12-20 breaths per minute.

✓ Correct Answer: C. Montelukast